267 related articles for article (PubMed ID: 26863030)
1. On the Road (to a Cure?)--Stem-Cell Tourism and Lessons for Gene Editing.
Charo RA
N Engl J Med; 2016 Mar; 374(10):901-3. PubMed ID: 26863030
[No Abstract] [Full Text] [Related]
2. New Japanese initiatives on stem cell therapies.
Konomi K; Tobita M; Kimura K; Sato D
Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
[TBL] [Abstract][Full Text] [Related]
3. Rejuvenating Regenerative Medicine Regulation.
Charo RA; Sipp D
N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
[No Abstract] [Full Text] [Related]
4. Foreword: A compendium on latest developments in stem cell research and cell therapy applications.
Koka PS; Khanna A
J Stem Cells; 2009; 4(2):81-3. PubMed ID: 20232593
[No Abstract] [Full Text] [Related]
5. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
Hyun I
J Law Med Ethics; 2010; 38(2):277-85. PubMed ID: 20579251
[TBL] [Abstract][Full Text] [Related]
6. A RAT by Another Name: 21
Riley MF
Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
[No Abstract] [Full Text] [Related]
7. Issue of transparency in stem cell therapy.
Akhtar J
J Coll Physicians Surg Pak; 2012 Jun; 22(6):347-8. PubMed ID: 22630090
[No Abstract] [Full Text] [Related]
8. STER science and cardiothoracic surgery: an Asian perspective.
Chiu RC
Asian Cardiovasc Thorac Ann; 2008 Oct; 16(5):351-2. PubMed ID: 18812339
[No Abstract] [Full Text] [Related]
9. [CRISPR/Cas system for genome editing in pluripotent stem cells].
Vasil'eva EA; Melino D; Barlev NA
Tsitologiia; 2015; 57(1):19-30. PubMed ID: 25872372
[TBL] [Abstract][Full Text] [Related]
10. FDA challenges stem-cell clinic.
Cyranoski D
Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
[No Abstract] [Full Text] [Related]
11. Stem cell research and policy in India: current scenario and future perspective.
Sharma A
J Stem Cells; 2009; 4(2):133-40. PubMed ID: 20232598
[TBL] [Abstract][Full Text] [Related]
12. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
Knoepfler PS
Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
[TBL] [Abstract][Full Text] [Related]
13. FDA's claims over stem cells upheld.
Cyranoski D
Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
[No Abstract] [Full Text] [Related]
14. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
von Tigerstrom B
Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
[TBL] [Abstract][Full Text] [Related]
15. Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?
Komatani TS
Pharm Pat Anal; 2014 Sep; 3(5):475-9. PubMed ID: 25374315
[No Abstract] [Full Text] [Related]
16. Stem cells in Texas: Cowboy culture.
Cyranoski D
Nature; 2013 Feb; 494(7436):166-8. PubMed ID: 23407522
[No Abstract] [Full Text] [Related]
17. Athletes' use of unproven stem cell therapies: adding to inappropriate media hype?
Caulfield T; McGuire A
Mol Ther; 2012 Sep; 20(9):1656-8. PubMed ID: 22945228
[No Abstract] [Full Text] [Related]
18. Can we assure quality without stifling innovation?
Miller L
Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):66-7. PubMed ID: 25457966
[TBL] [Abstract][Full Text] [Related]
19. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
Matthews KR; Iltis AS
BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611
[TBL] [Abstract][Full Text] [Related]
20. Bioethics Panels Open Door Slightly to Germline Gene Editing.
Lyon J
JAMA; 2017 Nov; 318(17):1639-1640. PubMed ID: 29049747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
